Fig. 1: PFS based on cytogenetic risk status. | Blood Cancer Journal

Fig. 1: PFS based on cytogenetic risk status.

From: Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Fig. 1

PFS in the ITT/biomarker risk population:* A standard and B high cytogenetic risk patients. PFS in patients with one prior line of therapy: C standard and D high cytogenetic risk patients. PFS progression-free survival, HR hazard ratio, CI confidence interval, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, ITT intent-to-treat. *Patients in the ITT population who met the biomarker criteria for risk assessment.

Back to article page